Please login to the form below

Not currently logged in
Email:
Password:

Vikas Sinha joins Verona as non-executive director

Brings strong US and financial experience to the UK drug development firm

Verona Pharma Vikas SinhaUK drug development company Verona Pharma has appointed Vikas Sinha as a non-executive director.

Currently executive vice president and chief financial officer at Alexion Pharmaceuticals, Sinha has served at the rare disease firm since 2005.

Prior to that he spent 11 years at Bayer, holding roles in the US, Canada, Japan and Germany, latterly as chief financial officer for Bayer Pharmaceuticals Corporation in the US.

Dr David Ebsworth, chairman of Verona Pharma, said: “Vikas' impressive financial background, including his US expertise, makes him a very welcome addition to our Board of Directors. 

“I have known Vikas for many years having worked together at Bayer and hold his impressive track record in high regard. We are pleased that Vikas will be joining our Board at such a pivotal time, as we progress our lead asset, RPL554, into a phase IIb clinical trial programme.”

A potential first-in-class treatment for chronic obstructive pulmonary disease (COPD), Verona Pharma's RPL554 is being tested as a nebulised maintenance treatment for patients with moderate to severe disease.

13th September 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics